JP2021529557A5 - - Google Patents

Info

Publication number
JP2021529557A5
JP2021529557A5 JP2021522922A JP2021522922A JP2021529557A5 JP 2021529557 A5 JP2021529557 A5 JP 2021529557A5 JP 2021522922 A JP2021522922 A JP 2021522922A JP 2021522922 A JP2021522922 A JP 2021522922A JP 2021529557 A5 JP2021529557 A5 JP 2021529557A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
immunoglobulin
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021522922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039994 external-priority patent/WO2020006516A1/en
Publication of JP2021529557A publication Critical patent/JP2021529557A/ja
Publication of JP2021529557A5 publication Critical patent/JP2021529557A5/ja
Pending legal-status Critical Current

Links

JP2021522922A 2018-06-29 2019-06-28 抗腫瘍免疫チェックポイント調節因子アンタゴニスト Pending JP2021529557A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862691658P 2018-06-29 2018-06-29
US62/691,658 2018-06-29
US201962823989P 2019-03-26 2019-03-26
US62/823,989 2019-03-26
PCT/US2019/039994 WO2020006516A1 (en) 2018-06-29 2019-06-28 Antitumor immune checkpoint regulator antagonists

Publications (2)

Publication Number Publication Date
JP2021529557A JP2021529557A (ja) 2021-11-04
JP2021529557A5 true JP2021529557A5 (OSRAM) 2022-06-30

Family

ID=68985227

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021522920A Pending JP2021529556A (ja) 2018-06-29 2019-06-28 抗腫瘍アンタゴニスト
JP2021522921A Pending JP2021532170A (ja) 2018-06-29 2019-06-28 三重特異性アンタゴニスト
JP2021522922A Pending JP2021529557A (ja) 2018-06-29 2019-06-28 抗腫瘍免疫チェックポイント調節因子アンタゴニスト

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021522920A Pending JP2021529556A (ja) 2018-06-29 2019-06-28 抗腫瘍アンタゴニスト
JP2021522921A Pending JP2021532170A (ja) 2018-06-29 2019-06-28 三重特異性アンタゴニスト

Country Status (9)

Country Link
US (9) US10597453B2 (OSRAM)
EP (3) EP3813864A4 (OSRAM)
JP (3) JP2021529556A (OSRAM)
KR (1) KR102927975B1 (OSRAM)
CN (3) CN112739717B (OSRAM)
AU (1) AU2019293047B2 (OSRAM)
BR (1) BR112020026862A2 (OSRAM)
CA (1) CA3105101A1 (OSRAM)
WO (3) WO2020006516A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN109071656B (zh) * 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2020006516A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
EP3891182A4 (en) 2018-12-03 2022-08-17 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd RECOMBINANT PROTEIN AGAINST PD-L1 AND VEGF
TWI760751B (zh) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
EP3990116A1 (en) * 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4048704A4 (en) 2019-10-21 2023-11-22 Nanjing Leads Biolabs Co., Ltd. RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß
CA3154413A1 (en) 2019-11-01 2021-05-06 Yan Lan Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer
JP2023502585A (ja) 2019-11-05 2023-01-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療のための、PD-1、TGFβ、及びTIGITの組み合わせ阻害
KR20220131261A (ko) * 2020-01-10 2022-09-27 상하이 헨리우스 바이오테크, 인크. 항tigit항체, 이를 포함하는 다중 특이적 항체 및 그 사용 방법
JP7489468B2 (ja) * 2020-03-20 2024-05-23 レメゲン シーオー.,エルティーディー. 二重特異性融合タンパク質及びその応用
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
CN115461362A (zh) 2020-04-14 2022-12-09 葛兰素史密斯克莱知识产权发展有限公司 基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法
KR20230003178A (ko) * 2020-04-29 2023-01-05 치아타이 티안큉 파마수티컬 그룹 주식회사 PD-1 및 TGF-β에 대한 이중 기능성 단백질
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022059800A1 (en) * 2020-09-15 2022-03-24 Santen Pharmaceutical Co., Ltd. Bispecific binding molecules against vegf and ang2
CN116801906A (zh) 2020-11-02 2023-09-22 阿雷斯贸易股份有限公司 癌症的联合治疗
WO2022090529A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
CN114539415B (zh) * 2020-11-24 2024-02-02 普米斯生物技术(珠海)有限公司 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
WO2022132932A1 (en) * 2020-12-15 2022-06-23 The Trustees Of Columbia University In The City Of New York Method of enhancing immune response and cancer immunotherapy by targeting the cd58:cd2 axis
CN116917334B (zh) * 2021-02-22 2026-02-06 浙江道尔生物科技有限公司 一种具有抗癌活性的多结构域融合蛋白
CN117255809B (zh) * 2021-03-31 2025-05-30 杭州嘉因生物科技有限公司 靶向vegf和血管生成素的融合分子及其用途
CN115322259A (zh) * 2021-05-11 2022-11-11 正大天晴药业集团南京顺欣制药有限公司 针对PD-1和TGF-β的双功能蛋白
WO2022256820A1 (en) * 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
JP2024520764A (ja) 2021-06-07 2024-05-24 アレス トレーディング ソシエテ アノニム 癌の組み合わせ処置
JP2024523838A (ja) * 2021-06-09 2024-07-02 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ox40及び/又はpd-l1に結合する抗体及び二重特異性結合タンパク質
IL310292A (en) 2021-07-22 2024-03-01 Univ Dundee Medicinal myotains
CN113773401B (zh) * 2021-09-15 2023-06-20 宜明昂科生物医药技术(上海)股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
JP2024535768A (ja) * 2021-09-15 2024-10-02 江蘇恒瑞医薬股▲ふん▼有限公司 抗pvrig/tigit二重特異性抗体を含む医薬組成物
CN118159568A (zh) * 2021-10-21 2024-06-07 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途
CN116333135A (zh) * 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
GEAP202416581A (en) * 2022-01-13 2024-12-10 Ingenia Therapeutics Inc Vegf and tie2-binding fusion protein and uses thereof
CN116496407B (zh) * 2022-01-25 2025-08-15 上海菩莳医药科技有限公司 一种双功能融合蛋白及其制备方法和应用
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
CN116836281A (zh) * 2022-03-25 2023-10-03 英诺湖医药(杭州)有限公司 B7h3抗体及包含其的双功能抗体
WO2024017281A1 (zh) * 2022-07-20 2024-01-25 明慧医药(杭州)有限公司 多特异性抗体及其用途
CN119816524A (zh) * 2022-08-22 2025-04-11 浙江道尔生物科技有限公司 多结构域融合蛋白的用途
EP4698562A1 (en) * 2023-04-19 2026-02-25 Centessa Pharmaceuticals (UK) Limited Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
CN122003437A (zh) * 2023-09-28 2026-05-08 南京维立志博生物科技股份有限公司 抗fgfr2抗体和包含其的多特异性结合分子
WO2025076440A1 (en) * 2023-10-04 2025-04-10 Agenus Inc. TGFβRII EXTRACELLULAR REGION VARIANTS AND USES THEREOF
WO2025111816A1 (en) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3030025A (en) 1962-04-17 Thermostatic gas valve
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7067637B1 (en) 1992-02-12 2006-06-27 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Antibody or antibody fragments specific for a protein of the TGF-β family
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
CN1322126C (zh) 1998-02-04 2007-06-20 思罗姆-X股份有限公司 免疫原性降低和/或清除率降低的葡激酶衍生物的鉴定、生产和应用
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
PT1196186E (pt) 1999-07-12 2008-02-14 Genentech Inc Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
US6528959B2 (en) 2000-07-19 2003-03-04 Honda Giken Kogyo Kabushiki Kaisha Driving force control system for front-and-rear wheel drive vehicles
US20030161809A1 (en) 2000-10-02 2003-08-28 Houston L. L. Compositions and methods for the transport of biologically active agents across cellular barriers
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6874679B2 (en) 2001-10-12 2005-04-05 Innovative Packaging Designs, L.P. Container having sliding corner support
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7498414B2 (en) 2002-03-04 2009-03-03 Imclone Systems Incorporated Human antibodies specific to KDR and uses thereof
CA2384922C (en) 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
US7025982B2 (en) 2002-09-19 2006-04-11 Medtronic, Inc. Medical assembly suitable for long-term implantation and method for fabricating the same
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US7182135B2 (en) 2003-11-14 2007-02-27 Halliburton Energy Services, Inc. Plug systems and methods for using plugs in subterranean formations
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CA2572765C (en) * 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
CA2607448C (en) 2005-04-22 2014-11-18 Eli Lilly And Company Tgf beta 1 specific antibodies
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
ITBS20050066A1 (it) 2005-06-01 2006-12-02 Sys Tec S R L Metodo e macchina per allineare lastre di stampa flessografica su cilindri di stampa
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
ES2379194T3 (es) 2005-12-23 2012-04-23 Eli Lilly And Company Anticuerpos de unión a TGF-beta
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TGF-β 길항제 다중-표적 결합 단백질
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
GB0919074D0 (en) 2009-10-30 2009-12-16 Cambridge Reactor Design Ltd Crystallisation process and apparatus
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
PT2542590T (pt) * 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
ES2694411T3 (es) 2011-08-19 2018-12-20 Regeneron Pharmaceuticals, Inc. Anticuerpos anti-Tie2 y usos de los mismos
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
US8581886B2 (en) 2011-10-28 2013-11-12 Atmel Corporation Tuning algorithm for noise reduction in an active stylus
AU2012356894B2 (en) 2011-12-23 2018-01-18 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
CA2865464C (en) 2012-03-30 2022-07-12 Boehringer Ingelheim International Gmbh Ang2-binding molecules
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
EP2906295A4 (en) * 2012-10-15 2016-06-01 Oncomed Pharm Inc METHOD FOR THE TREATMENT OF EYE DISEASES
WO2014079000A1 (en) 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20160137717A1 (en) * 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
EP3105246B1 (en) 2014-02-10 2021-03-31 Merck Patent GmbH Targeted tgf beta inhibition
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US9994632B2 (en) * 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
KR20170072343A (ko) * 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
MY187045A (en) * 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
CN107466446B (zh) 2015-04-10 2021-02-12 Lg 电子株式会社 在无线通信系统中报告信道状态信息的方法及其设备
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN105111314B (zh) * 2015-08-13 2019-01-08 成都百世博生物技术有限公司 一种新型融合蛋白、药物组合物及其制备方法和用途
CA2996996A1 (en) * 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
CA3007135A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
CN109069638B (zh) * 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
MA45255A (fr) * 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
JP7461741B2 (ja) * 2016-06-20 2024-04-04 カイマブ・リミテッド 抗pd-l1およびil-2サイトカイン
CN109071656B (zh) * 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
WO2020006516A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
EP3990116A1 (en) * 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2022063114A1 (zh) * 2020-09-23 2022-03-31 海正生物制药有限公司 Tgfbr2-ecd突变体及包含其的融合蛋白与应用
WO2022256820A1 (en) * 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists

Similar Documents

Publication Publication Date Title
JP2021532170A5 (OSRAM)
JP2018035138A5 (OSRAM)
JP2021527431A5 (OSRAM)
JP2021521843A5 (OSRAM)
JP2020528768A5 (OSRAM)
JP2022510964A5 (OSRAM)
JP2020500538A5 (OSRAM)
HRP20201503T1 (hr) MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79
JP2023093753A5 (OSRAM)
JP2017530722A5 (OSRAM)
JP2022534135A5 (OSRAM)
JP2022509156A5 (OSRAM)
JP2022533538A5 (OSRAM)
JP2012532851A5 (OSRAM)
JP2025183307A5 (OSRAM)
JP2023545182A5 (OSRAM)
JP2020511946A5 (OSRAM)
JP2018512124A5 (OSRAM)
JP2025038088A5 (OSRAM)
JP2022516351A5 (OSRAM)
JP2020515277A5 (OSRAM)
JP2023545183A5 (OSRAM)
JP2023518153A5 (OSRAM)
JP2022545741A5 (OSRAM)
JP2018514193A5 (OSRAM)